Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Rasna Therapeutics Inc. | v449498_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
____________________________________________________________
Date of Report (Date of earliest event reported): September 27, 2016
RASNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
| Nevada | 333- 191083 | 39-2080103 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
|
420 Lexington Avenue, New York, NY |
10170 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: 201-994-9936
Active With Me, Inc.
(Former name or former address, if changed since last report)
Copies to:
Jeffrey Fessler, Esq.
61 Broadway, 32nd Floor
New York, New York 10006
Telephone: (212) 930-9700
Facsimile: (212) 202-7735
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On September 27, 2016, Rasna Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company effected a 3.25-for-1 forward split of its common stock, which went into effect for trading on a split-adjusted basis on Tuesday, September 20, 2016, as well as a name change and trading symbol change from Active With Me, Inc. and “ATVM” to Rasna Therapeutics, Inc. and “RASP,” effective as of September 27, 2016.
The information in this report (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
| Exhibit No . | Description |
| 99.1 | Press Release issued September 27, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: September 27, 2016
| ACTIVE WITH ME, INC. | |||
| By: | /s/ James Tripp | ||
| Name: James Tripp | |||
| Title: Chief Executive Officer | |||